UTHSC researchers identify three drugs as possible therapeutics for Covid-19

Three drugs, already approved for other uses in humans, have been identified as possible therapeutics for COVID-19, the illness caused by the SARS-CoV-2 virus.

ANI | Washington DC | Updated: 19-11-2020 18:35 IST | Created: 19-11-2020 18:35 IST
UTHSC researchers identify three drugs as possible therapeutics for Covid-19
Representative image . Image Credit: ANI

Three drugs, already approved for other uses in humans, have been identified as possible therapeutics for COVID-19, the illness caused by the SARS-CoV-2 virus. The finding is a product of work by researchers at the University of Tennessee Health Science Center (UTHSC) collaborating with those at the University of New Mexico.

Based on virtual and in vitro antiviral screening that began in the earlier months of the Covid-19 pandemic, the researchers led at UTHSC by Colleen Jonsson, PhD, identified zuclopenthixol, nebivolol, and amodiaquine as promising therapeutics for the virus in its early stages. Dr. Jonsson is a professor and the Endowed Van Vleet Chair of Excellence in Virology in the College of Medicine at UTHSC. She also directs the UTHSC Regional Biocontainment Laboratory (RBL), where this research was conducted. The university's RBL is one of roughly a dozen federally funded labs authorized to safely study contagious pathogens.

In a paper published in ACS Pharmacology and Translational Science, the researchers propose the drugs as possible candidates for testing in future clinical trials to improve immune response to the virus. Amodiaquine is an older antimalarial, zuclopenthixol is an antipsychotic, and nebivolol is a blood pressure medication. "Particularly in the context of this pandemic, there is a stringent need for high-quality studies that can provide critical knowledge concerning the COVID-19 disease and reliable treatment proposals," the paper states.

"With these caveats in mind, we conceived a computational workflow that included independent in vitro validation, followed by assessing emerging candidates in the context of available clinical pharmacology data with the aim of proposing suitable candidates for clinical studies for early stage (incubation and symptomatic phases) patients infected by SARS-CoV-2," the paper further states. "Given the need for improved efficacy and safety, we propose zuclopenthixol, nebivolol, and amodiaquine as potential candidates for clinical trials against the early phase of the SARS-CoV-2 infection," the researchers wrote.

Comparing the drugs to hydroxychloroquine, the anti-malarial drug most-frequently studied in clinical trials for use as a COVID-19 therapeutic, the researchers examined 4,000 approved drugs and found these three to act similarly to the hydroxychloroquine, and in some cases, more safely. The research indicates they may also improve efficacy when combined in lower doses with remdesivir, an anti-viral given an emergency use authorization by the United States Food and Drug Administration as a therapeutic for COVID-19.

"Think of it as a whack-a-mole game. Instead of having one hammer, you have two hammers, which is more effective. We're trying to give the scientific community two hammers, instead of one," said Tudor Oprea, MD, PhD, professor of Medicine and Pharmaceutical Sciences, chief of the UNM Division of Translational Informatics, and corresponding author on the paper. "This is a very exciting discovery and we are following up on the potential use of zuclopenthixol, nebivolol, and amodiaquine in additional research studies," Dr. Jonsson added. (ANI)

Also Read: Senzo Mchunu welcomes GEMS for validating executive's PhD qualification

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


  • READ MORE ON:
  • PhD

TRENDING

OPINION / BLOG / INTERVIEW

Blockchain in Healthcare: Opportunities and challenges

The use of blockchain in healthcare is a relatively new innovation with many of its uses still being explored and related technologies being developed, improved, and scaled. ...

Debate surrounding vaccine passports and development misses bigger picture

... ...

Blockchain vs IOTA: Looking for a better alternative

... ...

For stability, Iraq needs to crack down on corruption

... ...

Videos

Latest News

On vaccinating the globe, Blinken warns: 'We have to speed this up'

Vaccinating the globe against COVID-19 needs to be sped up to beat mutations of the virus, and the United States is looking at how it can do more to help, U.S. Secretary of State Antony Blinken said on Thursday.If the entire world doesnt do...

Dispute over COVID-19 deaths pits indigenous Brazilians against gov't

Native affairs agency Funai slammed for handling of the pandemic Indigenous leader subpoenaed by police for spreading fake news Judge denounces Funai for trying to silence indigenous activists By Fabio TeixeiraRIO DE JANEIRO, May 6 Thomso...

Spain says vaccine patent waiver is the way forward but not enough for poor countries

Spains government said on Thursday a U.S. proposal to waive patents on coronavirus vaccines signals the way forward but will not be enough to guarantee supplies to developing countries.Such a suspension of intellectual property rights will ...

Jaishankar expresses concern over attack on Maldivian leader Nasheed

External Affairs Minister S Jaishankar expressed deep concern on Thursday over an attack on former president of Maldives and speaker of the countrys parliament Mohamed Nasheed.According to reports, Nasheed was injured in an explosion in Mal...

Give Feedback